In early April I wrote a piece arguing that biotech stocks – using the iShares Nasdaq Biotech ETF (IBB) as a proxy – looked to be under distribution. At the time the IBB traded at approximately $340. My argument rested on negative divergences in the Shares Outstanding / Price action of the IBB, Block Money Flow trends, an increase in volatility, […]
Immunogen (NASDAQ:IMGN)Shares of Immunogen soared as much as 68% on June 1, 2015 after the company reported positive results in patients with platinum-resistant ovarian cancer. There are about 21,290 cases of women who get ovarian cancer in the United States each year. The problem is that a lot of these patients that take chemotherapy treatments such as platinum and paclitaxel […]
When an already attractive company in the small cap biotech space announces positive developments, it can take the market weeks or even months to price the news into the shares. Bret Jensen identifies three cheap companies with strong catalysts to power the next leg of their rallies.There are few things more exciting than buying a small biotech stock just before […]
One of our favorite biotech stocks of 2015, Organovo stock, has climbed 41% since the end of March. And that’s just the start for this revolutionary biotech investment.You see, Organovo Holdings Inc. (NYSEMKT: ONVO) is part of one of the most exciting biotech industries on the market. It’s called 3D bioprinting, and the applications are huge.Here’s a closer look at […]
For one top technician, there are only two names that matter to the market right now: Apple and biotech.”The correlation between Apple and biotech is outstanding,” technical analyst Carter Worth said Friday on CNBC’s “Options Action.” In what he’s dubbing the “king and queen” of the market, Worth said, “The way the two act, you’d think nothing else in the […]
The health-care sector is hot—but it’s not due just to the wild ride in booming biotech.The health-care sector as a whole has been a standout in the S&P 500, up 9 percent year-to-date through the end of May and the top sector gainer last month, with a 4 percent return. That’s compared to the S&P 500’s meager 2.3 percent for […]
On the pages of Investors Alley, Bret Jensen has a history of recommending biotech winners. Today, we’re following up on five of Bret’s most promising biotech recommendations that have staged big gains and could still be in the early innings of significant rallies. These stocks are still strong buys.The small biotech sector is one of the most volatile sectors of […]
Others note continued opportunity in biotech.Robert Christian, who analyzes hedge funds as head of research at K2 Advisors and Franklin Templeton Solutions, said biotech stock-focused managers stand out as one of his favorite strategies among the few dozen he tracks.Christian’s optimism rests on what he called exciting new technologies that justify higher company valuations.”Biotech used to be about making life […]
Sarepta Therapeutics (NASDAQ:SRPT)After the closing bell on May 19, 2015 shares of Sarepta Therapeutics were up as much as 38% in after-hours trading after the company reported that the FDA will allow the company to file a New Drug Application — NDA — for Eteplirsen. This drug Eteplirsen helps patients with Duchenne Muscular Dystrophy — DMD — to restore dystrophin […]
Eleven Biotherapeutics (EBIO – Snapshot Report) suffered a huge setback with its lead pipeline candidate failing in a late-stage study. Meanwhile, companies like bluebird (BLUE – Snapshot Report), Agios (AGIO – Snapshot Report) and Acceleron (XLRN – Snapshot Report) all got encouraging news on the regulatory front. Achillion (ACHN – Snapshot Report) struck a collaboration agreement with Johnson & Johnson […]
